STOCK TITAN
  1. Home
  2. News
  3. GOVX

GeoVax Labs, Inc. New - GOVX STOCK NEWS

Welcome to our dedicated page for GeoVax Labs New news (Ticker: GOVX), a resource for investors and traders seeking the latest updates and insights on GeoVax Labs New stock.

GeoVax Labs, Inc. (Nasdaq: GOVX) is a clinical-stage biotechnology company specializing in the development of human vaccines and immunotherapies against infectious diseases and cancers. Utilizing their innovative Modified Vaccinia Ankara-Virus-Like Particle (MVA-VLP) platform, GeoVax has a strong focus on creating vaccines that stimulate both humoral and cellular immune responses to various targeted infections.

GeoVax's product pipeline includes an advanced Covid-19 vaccine, GEO-CM04S1, which is currently undergoing three phase 2 clinical trials. This next-generation vaccine is designed to induce robust antibody and T-cell responses against multiple SARS-CoV-2 variants, including Delta and Omicron. GEO-CM04S1 is especially targeted at high-risk immunocompromised populations who may not respond adequately to existing vaccines.

In oncology, GeoVax is pioneering novel therapies with Gedeptin®, an oncolytic gene-directed therapy for solid tumors. Gedeptin® is in phase 1/2 clinical trials for advanced head and neck cancers, aiming to provide new treatment avenues for patients with limited options.

GeoVax has shown significant progress in vaccine development against other infectious diseases such as Mpox, smallpox, HIV, Zika, hemorrhagic fever viruses, and malaria. Their recent partnership with the National Institute of Allergy and Infectious Diseases (NIAID) has expanded their vaccine development license to include Mpox and smallpox, leveraging their MVA technology for broader immunological protection.

The company also focuses on intellectual property, holding over 115 granted or pending patents across 24 patent families. This robust IP portfolio enhances their competitive edge in the biopharmaceutical sector.

GeoVax's commitment to innovative research and scalable manufacturing solutions positions them as a key player in the fight against some of the world’s most threatening diseases. For more detailed information, visit their official website at www.geovax.com.

News

GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024

Rhea-AI Summary
GeoVax Labs, Inc. (GOVX) will report its 2023 financial results on February 29, 2024, after U.S. markets close. The company, a clinical-stage biotechnology firm, specializes in developing immunotherapies and vaccines for cancer and infectious diseases. A live conference call and webcast will follow the financial report for a corporate update and Q&A session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
conferences earnings
-
News

GeoVax to Present at the 2024 BIO CEO & Investor Conference

Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) announces its Chairman and CEO, David Dodd, will present at the 2024 BIO CEO & Investor Conference in New York. The company will also conduct one-on-one meetings during the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

GeoVax Announces Multiple Patent Issuances and Allowances

Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) announces strengthening of intellectual property assets for its cancer immunotherapy program, Marburg virus, and HIV vaccines. The company received patent approvals from the Japanese Patent Office and the U.S. Patent and Trademark Office for various technologies related to immunotherapies and vaccines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
none
News

GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster

Rhea-AI Summary
GeoVax Labs, Inc. announces positive initial safety and immune response findings from its Phase 2 clinical trial for its Covid-19 vaccine, GEO-CM04S1. The trial, evaluating GEO-CM04S1 as a heterologous booster in 63 healthy adults who had previously received the Pfizer or Moderna mRNA vaccine, showed no serious adverse events and documented statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants, including Delta and Omicron XBB 1.5. GEO-CM04S1 is designed to induce both antibody and T-cell responses to protect against severe disease caused by continually emerging variants of Covid-19.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.74%
Tags
clinical trial covid-19
-
News

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) has announced a 1-for-15 reverse stock split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market. The reverse split will be effective on January 30, 2024, with the Common Stock expected to begin trading on the split-adjusted basis on the Nasdaq Stock Exchange at the market open on January 31, 2024. The total number of issued and outstanding shares of Common Stock will be reduced proportionately from 29,757,823 shares to approximately 1,983,855 shares. The reverse split will not affect the rights and privileges of the holders of shares of Common Stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.45%
Tags
stock split
-
News

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) strengthens its team by appointing Dr. J. Marc Pipas, M.D., as the Executive Medical Director, Oncology, to support the clinical development and regulatory approval of Gedeptin® and other immune-oncology programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
News

GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients

Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) has announced the closure of patient enrollment for the Phase 1/2 clinical study evaluating Gedeptin® in patients suffering from advanced head and neck cancer. The study demonstrated safety, tolerability, and stabilization or shrinkage of injected tumors in patients receiving multiple cycles of Gedeptin, leading to expanded development for monotherapy and combination therapy. GeoVax plans to proceed with further Gedeptin investigations, including adjustments to the treatment regimen and combination with immune checkpoint inhibitors in advanced head and neck cancer, as well as for additional cancerous and non-cancerous tumor indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
clinical trial
-
News

GeoVax Announces Issuance of Malaria Vaccine Patent

Rhea-AI Summary
GeoVax Labs, a biotechnology company (Nasdaq: GOVX), has been issued Patent No. 11,857,611 by the U.S. Patent and Trademark Office for a multiple component vaccine to prevent and treat malaria. The patent covers compositions and methods utilizing GeoVax's modified vaccinia Ankara (MVA) vector expressing Plasmodium antigens. The company aims to address the global public health threat of malaria, which causes 227 million infections and 619,000 deaths annually.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
-
News

GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024

Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) to Present at Biotech Showcase and J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
conferences
News

GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox

Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) expands its License Agreement with the National Institute of Allergy and Infectious Diseases to include Mpox and smallpox as additional indications for the development of a vaccine against SARS-CoV-2 (COVID-19). The amendment allows GeoVax to use materials and patent rights owned by the National Institutes of Health in combination with the Company’s proprietary technology for the creation of preventive Modified Vaccinia Ankara Virus-Virus Like Particle (MVA-VLP) vaccines. The expansion offers the potential for a simplified vaccine regimen for protection against diseases associated with SARS-CoV-2 and orthopoxviruses, providing a significant opportunity for GeoVax's ongoing COVID-19 vaccine program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
covid-19

FAQ

What is the current stock price of GeoVax Labs New (GOVX)?

The current stock price of GeoVax Labs New (GOVX) is $1.91 as of January 31, 2025.

What is the market cap of GeoVax Labs New (GOVX)?

The market cap of GeoVax Labs New (GOVX) is approximately 17.7M.

What is GeoVax Labs, Inc.?

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancers using their MVA-VLP platform.

What is the MVA-VLP platform?

The MVA-VLP platform supports in vivo production of non-infectious virus-like particles that stimulate the immune system to fight targeted infections.

What are the main products in GeoVax’s pipeline?

GeoVax's key products include the GEO-CM04S1 Covid-19 vaccine and Gedeptin®, an oncolytic gene-directed therapy for solid tumors. They also have vaccines for Mpox, smallpox, and other infectious diseases under development.

What is the current status of the GEO-CM04S1 vaccine?

GEO-CM04S1 is currently in three Phase 2 clinical trials, targeting high-risk immunocompromised populations and evaluating its efficacy as a booster vaccine.

What is Gedeptin®?

Gedeptin® is GeoVax’s novel oncolytic gene-directed therapy for treating solid tumors, currently in Phase 1/2 clinical trials for advanced head and neck cancers.

How does GeoVax’s partnership with NIAID benefit their technology?

The partnership allows GeoVax to use NIAID's materials and patents to develop vaccines for Mpox, smallpox, and other infections using their MVA technology.

What recent achievements has GeoVax announced?

Recent achievements include positive interim results from Phase 2 trials for GEO-CM04S1, expanded licensing for Mpox and smallpox vaccines, and significant advancements in manufacturing capabilities.

How extensive is GeoVax’s intellectual property portfolio?

GeoVax holds over 115 granted or pending patents across 24 patent families, reinforcing their technological and competitive advantages in biotechnology.

How can I learn more about GeoVax Labs, Inc.?

For detailed information, visit GeoVax’s official website at www.geovax.com.
Stock GOVX logo
GeoVax Labs, Inc. New

Nasdaq:GOVX

GOVX Rankings

#5413 Ranked by Market Cap
N/A Ranked by Dividends

GOVX Stock Data

17.73M
9.39M
0.52%
10.83%
3.53%
Biotechnology
Pharmaceutical Preparations
Link
United States
SMYRNA